ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT)
CUSIP: 77313F106
Q2 2025 13F Holders as of 30 Jun 2025
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 109,265,652
- Total 13F shares
- 94,974,795
- Share change
- -13,115,545
- Total reported value
- $232,855,173
- Put/Call ratio
- 94%
- Price per share
- $2.45
- Number of holders
- 194
- Value change
- -$147,581,517
- Number of buys
- 120
- Number of sells
- 126
Quarterly Holders Quick Answers
What is CUSIP 77313F106?
CUSIP 77313F106 identifies RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 77313F106:
Top shareholders of RCKT - ROCKET PHARMACEUTICALS, INC. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RTW INVESTMENTS, LP |
13F
|
Company |
—
mixed-class rows
|
18,037,772
mixed-class rows
|
$117,993,889 | — | 31 Mar 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
13D/G
|
Company |
0.9%
from 13D/G
|
12,626,491
|
$84,218,695 | — | 31 Mar 2025 | |
| BlackRock, Inc. |
13F
|
Company |
6.7%
|
7,274,234
|
$48,519,146 | — | 31 Mar 2025 | |
| Roderick Wong |
3/4/5
|
Director, 10%+ Owner |
17%
|
18,236,124
|
$44,689,444 | — | 18 Jun 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
6.1%
|
6,617,784
|
$44,140,620 | — | 31 Mar 2025 | |
| MAVERICK CAPITAL LTD |
13F
|
Company |
4.8%
|
5,199,218
|
$34,678,784 | — | 31 Mar 2025 | |
| WESTFIELD CAPITAL MANAGEMENT CO LP |
13F
|
Company |
4.4%
|
4,820,701
|
$32,154,076 | — | 31 Mar 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
3%
|
3,290,843
|
$24,967,291 | — | 31 Mar 2025 | |
| STATE STREET CORP |
13F
|
Company |
3.4%
|
3,705,461
|
$24,715,425 | — | 31 Mar 2025 | |
| SUVRETTA CAPITAL MANAGEMENT, LLC |
13F
|
Company |
3.2%
|
3,502,000
|
$23,358,340 | — | 31 Mar 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
2.8%
|
3,043,682
|
$20,302,000 | — | 31 Mar 2025 | |
| MORGAN STANLEY |
13F
|
Company |
2.4%
|
2,641,892
|
$17,621,420 | — | 31 Mar 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.8%
|
1,994,044
|
$13,303,253 | — | 31 Mar 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
1.5%
|
1,618,265
|
$10,793,828 | — | 31 Mar 2025 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
1,826,307
mixed-class rows
|
$10,079,970 | — | 31 Mar 2025 | |
| Prosight Management, LP |
13F
|
Company |
1.4%
|
1,480,000
|
$9,871,600 | — | 31 Mar 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
1.2%
|
1,317,969
|
$8,790,853 | — | 31 Mar 2025 | |
| Novo Holdings A/S |
13F
|
Company |
1%
|
1,100,000
|
$7,337,000 | — | 31 Mar 2025 | |
| TORONTO DOMINION BANK |
13F
|
Company |
1%
|
1,100,000
|
$7,337,000 | — | 31 Mar 2025 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1%
|
1,097,079
|
$7,317,517 | — | 31 Mar 2025 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.99%
|
1,079,025
|
$7,197,097 | — | 31 Mar 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.91%
|
995,690
|
$6,641,250 | — | 31 Mar 2025 | |
| Kinnari Patel |
3/4/5
|
President, Head of R&D and Chief Operating Officer |
—
mixed-class rows
|
745,842
mixed-class rows
|
$6,417,297 | -$14,142 | 20 May 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.8%
|
870,308
|
$5,804,955 | — | 31 Mar 2025 | |
| TANG CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.78%
|
850,000
|
$5,669,500 | — | 31 Mar 2025 | |
| COMERICA BANK |
13F
|
Company |
0.75%
|
815,989
|
$5,442,647 | — | 31 Mar 2025 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.71%
|
770,691
|
$5,140,509 | — | 31 Mar 2025 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.68%
|
747,147
|
$4,983,470 | — | 31 Mar 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.64%
|
700,301
|
$4,671,008 | — | 31 Mar 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.62%
|
675,481
|
$4,505,458 | — | 31 Mar 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.6%
|
652,865
|
$4,354,610 | — | 31 Mar 2025 | |
| UBS Group AG |
13F
|
Company |
0.59%
|
647,830
|
$4,321,026 | — | 31 Mar 2025 | |
| Nantahala Capital Management, LLC |
13F
|
Company |
0.58%
|
629,749
|
$4,200,426 | — | 31 Mar 2025 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
0.56%
|
610,089
|
$4,069,294 | — | 31 Mar 2025 | |
| Siren, L.L.C. |
13F
|
Individual |
0.54%
|
591,263
|
$3,943,724 | — | 31 Mar 2025 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.53%
|
577,488
|
$3,853,483 | — | 31 Mar 2025 | |
| SCHRODER INVESTMENT MANAGEMENT GROUP |
13F
|
Company |
0.38%
|
413,550
|
$3,138,845 | — | 31 Mar 2025 | |
| MYDA Advisors LLC |
13F
|
Company |
0.42%
|
460,381
|
$3,070,741 | — | 31 Mar 2025 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.4%
|
438,617
|
$2,925,574 | — | 31 Mar 2025 | |
| Privium Fund Management B.V. |
13F
|
Company |
0.4%
|
432,760
|
$2,886,509 | — | 31 Mar 2025 | |
| Voss Capital, LP |
13F
|
Company |
0.4%
|
432,240
|
$2,883,041 | — | 31 Mar 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.39%
|
421,487
|
$2,811,318 | — | 31 Mar 2025 | |
| FEDERATED HERMES, INC. |
13F
|
Company |
0.38%
|
414,497
|
$2,764,695 | — | 31 Mar 2025 | |
| Invesco Ltd. |
13F
|
Company |
0.37%
|
400,969
|
$2,674,463 | — | 31 Mar 2025 | |
| M28 Capital Management LP |
13F
|
Company |
0.35%
|
385,680
|
$2,572,486 | — | 31 Mar 2025 | |
| Gotham Makker |
3/4/5
|
Director |
—
mixed-class rows
|
1,037,149
mixed-class rows
|
$2,545,450 | — | 18 Jun 2025 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.32%
|
352,957
|
$2,354,223 | — | 31 Mar 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.31%
|
338,474
|
$2,257,622 | — | 31 Mar 2025 | |
| Sovran Advisors, LLC |
13F
|
Company |
0.3%
|
323,091
|
$2,045,166 | — | 31 Mar 2025 | |
| Walleye Capital LLC |
13F
|
Company |
—
mixed-class rows
|
953,057
mixed-class rows
|
$1,946,178 | — | 31 Mar 2025 |
Institutional Holders of ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT) as of Q2 2025
As of 30 Jun 2025,
ROCKET PHARMACEUTICALS, INC. - Common Stock (RCKT) was held by
194 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
94,974,795 shares.
The largest 10 holders included
RTW INVESTMENTS, LP, MAVERICK CAPITAL LTD, BlackRock, Inc., VANGUARD GROUP INC, SUVRETTA CAPITAL MANAGEMENT, LLC, MPM BIOIMPACT LLC, MORGAN STANLEY, MILLENNIUM MANAGEMENT LLC, GEODE CAPITAL MANAGEMENT, LLC, and Newtyn Management, LLC.
This page lists
194
institutional shareholders reporting positions in this security
for the Q2 2025 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2025 vs Q1 2025 Across Filers
Q1 2025 holders
233
Q2 2025 holders
194
Holder diff
-39
| Investor | Q1 2025 Shares | Q2 2025 Shares | Share Diff | Share Chg % | Q1 2025 Value $ | Q2 2025 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.